


FR194738

Cat. No.:	HY-100303A		
CAS No.:	204067-52-7		
Molecular Formula:	C ₂₇ H ₃₈ ClNO ₂ S		
Molecular Weight:	476.11		
Target:	Others		
Pathway:	Others		
Storage:	Pure form	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



BIOLOGICAL ACTIVITY

Description	FR194738 is a squalene epoxidase inhibitor. FR194738 inhibits squalene epoxidase activity in HepG2 cell homogenates with an IC ₅₀ of 9.8 nM.
IC₅₀ & Target	IC ₅₀ : 9.8 nM (squalene epoxidase, in HepG2 cell homogenates) ^[1]
In Vitro	In intact HepG2 cells, FR194738 concentration-dependently inhibits the incorporation of [¹⁴ C]acetate into free cholesterol and cholesteryl ester, with IC ₅₀ s of 4.9 and 8.0 nM, respectively. FR194738 induces intracellular [¹⁴ C]squalene accumulation. FR194738 increases the incorporation of [¹⁴ C]acetate into squalene, an intermediate of cholesterol synthesis ^[1] . FR194738 potently inhibits squalene epoxidase (SE) in HepG2 cell homogenate and liver microsomes in dogs and rats. The inhibitory effect of FR194738 in comparison to the HMG-CoA reductase inhibitors, Simvastatin, Fluvastatin and Pravastatin, on cholesterol biosynthesis in HepG2 cells is examined. Among these compounds, FR194738 is the most potent, with an IC ₅₀ of 2.1 nM. The IC ₅₀ s of Simvastatin, Fluvastatin and Pravastatin are 40, 28 and 5100 nM, respectively ^[2] . FR194738 inhibits hamster liver microsomal squalene epoxidase activity in a concentration-dependent manner with an IC ₅₀ of 14 nM ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Serum lipid levels in hamsters after daily administration of FR194738 and Pravastatin for 10 d are measured. FR194738 reduces the serum levels of total, non high density lipoprotein (HDL) and HDL cholesterol, and triglyceride. Treatment of hamsters with FR194738 increases HMG-CoA reductase activity by 1.3-fold at 32 mg/kg compared to the control group and does not significantly change that at 100 mg/kg ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Cell Assay ^[1]	HepG2 cells are grown in 225 cm ² culture flasks, and incubated for 18 h in medium A containing 10% human lipoprotein deficient serum and 1 μM L-654,969 to increase their squalene epoxidase activity. The HepG2 cells are washed and harvested by trypsin treatment. After centrifugation (1000×g, 5 min at 4°C), the supernatant fraction is removed by aspiration. The cell pellet is frozen and kept at -80 °C until use. On the day of the experiment, the stocked cell pellet is thawed, ruptured by sonication (5 s at 4°C) in 0.1 M Tris-HCl, pH 7.5 containing 1 mM EDTA, mixed with one-fourth volume of 2% Triton X-100, stood at 4°C for 30 min, and assayed for squalene epoxidase activity with some modifications. Aliquots of
----------------------------------	---

the mixture are incubated for 90 min at 37 °C with or without test compound (FR194738; 0.01 nM, 0.1 nM, 1 nM, 10 nM, 100 nM, 1 μM, and 10 μM) dissolved in DMSO (final 1%) in a final volume of 0.3 mL containing 0.1 M Tris-HCl, pH 7.5, 1 mM EDTA, 1 mM NADPH, 0.1 mM FAD, 0.3 mM AMO1618, an inhibitor of 2,3-oxidosqualene cyclase, 0.17% Triton X-100, and 8 μM [³H]squalene (3.7 kBq) dispersed in 0.075% Tween 80. The reaction is stopped by the addition of 0.3 mL of 10% ethanolic KOH. After incubation for 90 min at 75°C, non-saponifiable materials are extracted with 2 mL of petroleum ether. The extracts are evaporated under a nitrogen stream. The residue is taken up in a small volume of diethylether, spotted on a silica gel thin layer chromatography (TLC) plate and developed in benzene/ethyl acetate (99.5:0.5, v/v)^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration ^[3]

Hamsters^[3]
Six-week-old male golden Syrian hamsters (70-110 g) are used. Drugs are administered as a diet mixture for 10 d. Blood samples are collected via heart puncture under ether anesthesia and serum is prepared by centrifugation. The dose of 0.32% in diet corresponds to 127 and 116 mg/kg/d for FR194738 and Pravastatin, respectively, calculated from body weight and food intake.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Sawada M, et al. Effect of FR194738, a potent inhibitor of squalene epoxidase, on cholesterol metabolism in HepG2 cells. *Eur J Pharmacol.* 2001 Nov 9;431(1):11-6.
- [2]. Sawada M, et al. Synthesis and biological activity of a novel squalene epoxidase inhibitor, FR194738. *Bioorg Med Chem Lett.* 2004 Feb 9;14(3):633-7.
- [3]. Sawada M, et al. Inhibition of cholesterol synthesis causes both hypercholesterolemia and hypocholesterolemia in hamsters. *Biol Pharm Bull.* 2002 Dec;25(12):1577-82.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA